Icatibant

BeschreibungHoe 140 (D-Arg-[Hyp3, Thi5, D-Tic7, Oic8]-bradykinin), on bradykinin- and platelet-activating factor (PAF)-induced bronchoconstriction and airway microvascular leakage in anesthetized guinea pigs. Hoe 140 is highly potent and long-acting in inhibiting BK-induced hypotensive responses in the rat. Four hours after s.c. administration of 20nmol kg-1, inhibition still amounted to 60% whereas the effect of 200nmol kg-1 of d-Arg-[Hyp2, Thi5,8, d-Phe7]BK was not significant[1-2].

HistoryIcatibant, developed by Germany's Jerini AG (which was acquired by Shire in 2008 and subsequently by Takeda), is a specific bradykinin B2 receptor antagonist used to treat acute episodes of hereditary angioedema. It works by inhibiting the effects of bradykinin, which is associated with localized swelling, inflammation, and pain. First approved in the European Union in 2008 under the trade name Firazyr for the treatment of acute HAE attacks in adults, it received accelerated approval from the FDA in 2011 via priority review for acute HAE attacks in patients aged 18 years and older. In 2017, the European Union further expanded its approved indications to include pediatric and adolescent HAE patients aged 2 years and above.

VerwendenIcatibant is an antagonist of the human bradykinin B2 receptor (B2R), that can be used for the treatment of hereditary angioedema (HAE). Upon administration, icatibant targets and binds to B2R, thereby preventing bradykinin from binding to the B2R. This may prevent bradykinin/B2R-mediated vasodilation, the resulting increase in vascular permeability, and the swelling, inflammation, and pain associated with HAE. This may also prevent or improve pulmonary edema not associated with HAE and improve the associated decrease in blood oxygen levels.